121 candidates register for PhD in various disease areas at CSIR-CDRI

New Delhi: CSIR- Central Drug Research Institute (CSIR-CDRI), a premier drug research institute of India was inaugurated on 17th Feb 1951 by the then Prime Minister of India Pt. Jawaharlal Nehru with a vision to strengthen and advance the field of drug research and development in the country. The Institute has made significant accomplishments in the pursuit of its mission to new drugs and technologies for affordable healthcare for all, generation of knowledge base and nurturing future leaders for the healthcare sector.

Today, it has become a unique model for modernized drug research in India – having everything under one roof, from synthesis, screening, development studies, process up-scaling to clinical studies. Unique achievements of the Institute include discovery and development of 14 new drugs, of which, Arteether (Brand Name: E-mal), BESEB (Brand Name: Memory Sure), Centchroman (Brand Name: Saheli/Chhaya), Reunion are currently in market; transferred more than 130 indigenous technologies to the pharmaceutical companies, a significant contribution in the metamorphosis of the Indian Pharma Industry. So far, more than 10,000 research articles have been published by the Institute in peer-reviewed journals. It has obtained more than 350 Indian patents and 90 international patents.

CSIR-CDRI is contributing to human resource development in line with the need of Nation since its inception and produced more than 1800 Ph.Ds. Several of its Alumni have occupied the highest positions in national and international academic institutions, biotech and pharma industries.

In continuation of this old legacy, the academic session starting from January 2020, a total of 121 NET qualified candidates joined for CSIR-CDRI Ph.D. Program in thrust area of research including addressing Biological Processes for designing new strategies of intervention in Parasitic Diseases (Malaria, Filariasis, Leishmaniasis); Bone Health and Metabolic Bone Diseases; AMR: Drug Resistant-Mycobacterial Infection & ESKAPE Pathogens; Neuroscience and ageing biology; Cancer and related disorders; Advance knowledge frontiers in the area of life style diseases and reproductive health; and Pre-clinical studies in Drug Development and Translation: Development of New Drug Entities, Phytopharmaceuticals and Standardized Extracts

Director, Professor Tapas Kumar Kundu conveyed his best wishes to the newly joined research scholars for their bright and splendid future. CSIR-CDRI PhD Program coordinators Dr Saman Habib (AcSIR PhD Program) and Dr Sanjeev Yadav (JNU PhD Program), briefed about the Pre-PhD course structure and other important details during the orientation program. All the faculty members were also present during the program.